 - Mavrilimumab r educe d t ime - to - f lare and i ncrease d s ustained r emission in Phase 2 giant cell arteritis clinical t rial - - Primary and secondary efficacy endpoints achieved statistical significan ce - - Results were consistent across new onset and relapsing refractory cohorts - 